Share

Competition

Excessive Pricing in Pharmaceuticals

 

 28 November 2018  Paris  

Affordable access to many drugs is made difficult by high prices. At the same time, serious questions are being asked about the degree of innovation and value offered by increasingly costly treatments.

A number of competition enforcement actions against excessive pricing have recently taken place in the pharmaceutical sector, despite competition authorities usually being reluctant to intervene directly against high prices. In common with other instances of application of competition law in the pharmaceutical sector, these cases require a deep understanding of market dynamics and sectoral regulation, and of the various regulatory responses that may be deployed to address high prices.

In November 2018, the OECD held a discussion on excessive prices at the intersection between competition law and regulated sectors such as pharma.

All related materials for the discussion are available on this page.

» Read the OECD background note EN FR

» View the full list of OECD best practice roundtables on competition policy

 

INVITED SPEAKERS

John DAVIES Bio  
Senior Vice President, Compass Lexecon 

Margherita COLANGELO Bio 
Associate Professor of Comparative Law, University of Roma Tre

Margaret KYLE Bio 
Professor of Economics, MINES Paris Tech

 

KEY PAPERS 

» OECD background note • Note de référence de l'OCDE 

Summaries of contributions

Canada

Chinese Taipei

Denmark

EU

India

Indonesia

Israel

Italy

Kazakhstan

Lithuania

Netherlands

Russian Federation

South Africa

Spain

Ukraine

United Kingdom

United States

BEUC

BIAC

 


» Read the OECD background note

» Watch a video about the other topics under discussion in Nov 2018

» OECD Competition Youtube channel

 

 

 

 PRESENTATIONS

 

RELATED DOCUMENTS AND LINKS

Competition issues in the distribution of pharmaceuticals, 2014 

Competition and Generic Pharmaceuticals, 2014

Excessive Prices, 2011

Generic Pharmaceuticals, 2009

Monopsony and Buyer Power, 2008

Competition and Regulation Issues in the Pharmaceutical Industry, 2000

RELATED TOPICS

Abuse of dominance and monopolisation

Liberalisation and competition intervention in regulated sectors

OECD best practice roundtables on competition

More OECD work on competition 

 

Related Documents